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1. INTRODUCTION {#dmrr3062-sec-0005}
===============

High glycemic variability is common among patients with type 2 diabetes mellitus (T2DM)[1](#dmrr3062-bib-0001){ref-type="ref"} and is a key contributor to complications associated with inadequate glycemic control.[2](#dmrr3062-bib-0002){ref-type="ref"}, [3](#dmrr3062-bib-0003){ref-type="ref"} The assessment of postprandial blood glucose (BG) for management of hyperglycemia in patients with T2DM is well recognized, and guidelines now recommend targeting both pre‐ and postprandial BG to maintain effective glycemic control.[3](#dmrr3062-bib-0003){ref-type="ref"} However, ethnic differences in the glycemic response and pathophysiology of T2DM may have implications for how T2DM is managed among different populations and for treatment outcomes.[4](#dmrr3062-bib-0004){ref-type="ref"}, [5](#dmrr3062-bib-0005){ref-type="ref"}, [6](#dmrr3062-bib-0006){ref-type="ref"}, [7](#dmrr3062-bib-0007){ref-type="ref"}

The prevalence of T2DM in Asian populations has increased rapidly in recent years and is associated with high levels of morbidity and mortality.[8](#dmrr3062-bib-0008){ref-type="ref"} This increase is partly due to changes in lifestyles and diet, earlier onset of T2DM among these populations, and differences in insulin secretion and resistance compared with Caucasian populations.[4](#dmrr3062-bib-0004){ref-type="ref"}, [5](#dmrr3062-bib-0005){ref-type="ref"}, [6](#dmrr3062-bib-0006){ref-type="ref"}, [7](#dmrr3062-bib-0007){ref-type="ref"} In addition, evidence from studies in healthy subjects suggests that the carbohydrate‐rich traditional Asian diet contributes to hyperglycemia[9](#dmrr3062-bib-0009){ref-type="ref"} and that postprandial hyperglycemia in response to the same glycemic load is higher in Asians than in Caucasians.[4](#dmrr3062-bib-0004){ref-type="ref"} Consequently, studies conducted in Asian patients with T2DM have shown postprandial BG to be important for management of hyperglycemia in patients on oral antihyperglycemic medication (OAM)[10](#dmrr3062-bib-0010){ref-type="ref"} or insulin.[11](#dmrr3062-bib-0011){ref-type="ref"} Despite this, few studies have directly compared BG profiles between Asian and Caucasian patients with T2DM.[12](#dmrr3062-bib-0012){ref-type="ref"}

Findings from a post hoc subgroup analysis of data from a large clinical trial (PARADIGM) of insulin‐naive patients with T2DM[13](#dmrr3062-bib-0013){ref-type="ref"} suggest that East Asian patients who have not started injectable therapy have higher postprandial BG excursions than Caucasian patients.[12](#dmrr3062-bib-0012){ref-type="ref"} However, this study was not designed to assess the possible effect of race or ethnicity on BG profiles before insulin initiation and statistical analysis of the differences in postprandial BG excursion between ethnic groups was not reported.

The primary objective of this study was to compare BG excursions between East Asian and Caucasian patients with T2DM who were injection‐naive, had inadequate glycemic control with OAMs, and who required initiation with injectable therapy. To address this objective, we conducted a retrospective pooled analysis of individual patient data from clinical trials including East Asian and/or Caucasian patients from two Eli Lilly sponsored programs. In addition, we conducted a systematic review of the peer‐reviewed literature with published summary data to identify studies reporting baseline BG or BG excursion data for patients who met the inclusion criteria.

2. MATERIALS AND METHODS {#dmrr3062-sec-0006}
========================

2.1. Pooled analysis {#dmrr3062-sec-0007}
--------------------

### 2.1.1. Eligibility criteria {#dmrr3062-sec-0008}

In this retrospective post hoc analysis, individual patient data were pooled from completed clinical trials from the Eli Lilly insulin lispro injection (Humalog®) or dulaglutide (Trulicity™) development program. All randomized and nonrandomized clinical trials were eligible for inclusion if they met the following criteria: first patient visit was on or after 1997; enrolled male or female adult (≥18 years) patients with T2DM who were injection‐naive (or had completed a sufficient washout period per individual study requirements); had inadequate glycemic control with OAMs, and required initiation with injectable therapy; and had baseline data for self‐monitored blood glucose (SMBG). As only baseline data were included in the analyses, there were no restrictions on study interventions or treatment duration.

### 2.1.2. Baseline and analysis variables {#dmrr3062-sec-0009}

The analyses included subpopulations of East Asian and Caucasian patients identified by race/ethnicity as reported in the case report forms. Patients were classified as East Asian if the reported race/ethnicity was East Asian or Asian, and where the patient was located in China, Japan, the Republic of Korea, Hong Kong, or Taiwan. Patients were classified as Caucasian if the reported race/ethnicity was White.

Data extracted from patient‐level records included baseline data for age (years), gender, body weight (kg), body mass index (kg/m^2^), duration of diabetes (years), glycated haemoglobin (HbA1c, %), and breakfast, lunch, dinner, and daily average preprandial BG, postprandial BG, and BG excursion based on finger stick SMBG (mmol/L) measurements. If BG excursions were not reported, these were derived from preprandial and postprandial BG measurements.

The primary outcome was BG excursion defined as the difference between preprandial and postprandial BG at breakfast. Secondary outcomes included BG excursion at lunch and dinner, and the daily average BG excursion.

### 2.1.3. Statistical analysis {#dmrr3062-sec-0010}

The full analysis set included all eligible randomized patients or all eligible enrolled patients from nonrandomized studies. Mean BG excursion at baseline was compared between East Asian and Caucasian patients using an analysis of covariance. The model included race as the fixed effect and baseline body weight, baseline HbA1c, age, and duration of T2DM as covariates. There was no imputation for missing BG measurements. Data were reported as mean (standard deviation) or least‐squares mean (standard error of the mean). Statistical analyses were conducted using SAS® Version 9.4 (SAS Institute, Cary, NC, USA).

2.2. Systematic review {#dmrr3062-sec-0011}
----------------------

The methodology for the systematic review is reported in the Supplementary Appendix.

3. RESULTS {#dmrr3062-sec-0012}
==========

3.1. Pooled analysis of clinical trials {#dmrr3062-sec-0013}
---------------------------------------

### 3.1.1. Study selection and patient population {#dmrr3062-sec-0014}

Of the 37 clinical trials identified, 21 met the eligibility criteria (Table [1](#dmrr3062-tbl-0001){ref-type="table"}). A total of 6779 Caucasian patients and 1638 East Asian patients from the 21 trials met the criteria for inclusion and their data were pooled for the analyses. As all clinical trials were part of two Eli Lilly clinical development programs, the trials had similar procedures and eligibility criteria. All procedures for the clinical trials were conducted in accordance with the ethical standards at each site and the relevant Declaration of Helsinki at the time the studies were conducted. Informed consent was obtained from all trial participants.

###### 

Clinical studies included in the pooled analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Eli Lilly Identifier CT.gov Number                    Key Inclusion Criteria at Enrolment                Analysis Groups (N) Caucasian = 6779 East Asian = 1638                                                                  Patient Characteristics at Baseline (Before Treatment with Study Drug), Mean (SD)                                                                                                                                       
  ----------------------------------------------------- -------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ------------------ -------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------
  H9X‐JE‐GBDQ\                                          7.0‐11.0%                                          Stable dose (≥8 wk) of SU, BG, TZD, α‐GI, or glinide monotherapy for ≥3 mo                                              EA: 394                                                                             EA: 57.4 (10.96)   EA: 71.4 (13.26)                                         EA: 8.5 (1.11)                                          EA: 7.7 (6.29)
   NCT01468181                                                                                                                                                                                                                                                                                                                                                                                                                                             

  H9X‐JE‐GBDY\                                          7.0‐10.0%                                          Stable dose (≥8 wk) SU or BG                                                                                            EA: 361                                                                             EA: 56.8 (10.92)   EA: 71.0 (13.71)                                         EA: 8.0 (0.85)                                          EA: 8.8 (6.41)
   NCT01584232                                                                                                                                                                                                                                                                                                                                                                                                                                             

  H9X‐MC‐GBCF\                                          7.0‐9.5% or \>8.0‐9.5% (diet & exercise)           Diet and exercise, met, OAM, or met + OAM                                                                               C: 613\                                                                             C: 56.2 (9.46)\    C: 93.5 (16.05)\                                         C: 8.1[a](#dmrr3062-note-0002){ref-type="fn"} (1.06)\   C: 7.1 (5.13)\
   NCT00734474                                                                                                                                                                                                                     EA: 178                                                                             EA: 52.1 (10.31)   EA: 74.0 (10.39)                                         EA: 8.2 (1.12)                                          EA: 6.9 (5.09)

  H9X‐MC‐GBCJ\                                          \>7.0‐10.5%                                        Any combination of 2 of: SU, BG, TZD, DPP‐IV inhibitors                                                                 C: 151                                                                              C: 59.9 (10.83)    C: 98.9 (17.23)                                          C: 8.1[a](#dmrr3062-note-0002){ref-type="fn"} (0.88)    C: 8.7 (6.93)
   NCT00630825                                                                                                                                                                                                                                                                                                                                                                                                                                             

  H9X‐MC‐GBDA\                                          1 OAM: 7.0‐11.0%\                                  ≤3 OAMs                                                                                                                 C: 728                                                                              C: 56.7 (9.65)     C: 99.0 (18.82)                                          C: 8.1 (1.37)                                           C: 8.7 (5.40)
   NCT01064687                                          2/3 OAM: 7.0‐10.0%                                                                                                                                                                                                                                                                                                                                                                                 

  H9X‐MC‐GBDB\                                          1 OAM: 7.0‐11.0%\                                  ≤3 OAMs                                                                                                                 C: 571\                                                                             C: 58.5 (9.08)\    C: 91.4 (17.77)\                                         C: 8.1 (0.96)\                                          C: 9.5 (6.08)\
   NCT01075282                                          2/3 OAM: 7.0‐10.0%                                                                                                                                                         EA: 43                                                                              EA: 53.9 (8.66)    EA: 71.0 (10.96)                                         EA: 8.6 (1.22)                                          EA: 9.3 (6.12)

  H9X‐MC‐GBDE\                                          7.0‐10.0%                                          Diet and exercise, stable dose (≥3 mo) met (≥1500 mg/day)                                                               C: 515                                                                              C: 57.3 (9.35)     C: 94.8 (18.73)                                          C: 8.0 (0.78)                                           C: 7.2 (5.48)
   NCT01624259                                                                                                                                                                                                                                                                                                                                                                                                                                             

  H9X‐MC‐GBDG\                                          7.0‐9.5%                                           Stable dose SU (≥50% max dose) for ≥3 mo                                                                                C: 250                                                                              C: 58.4 (9.80)     C: 86.6 (17.06)                                          C: 8.4 (0.71)                                           C: 7.6 (4.94)
   NCT01769378                                                                                                                                                                                                                                                                                                                                                                                                                                             

  H9X‐MC‐GBDN\                                          7.0‐9.5%                                           ≥1 OAM for ≥1 mo                                                                                                        C: 608                                                                              C: 57.0 (10.30)    C: 92.9 (19.75)                                          C: 7.9 (0.75)                                           C: 8.5 (5.93)
   NCT01149421                                                                                                                                                                                                                                                                                                                                                                                                                                             

  F3Z‐CR‐IOPH\                                          7.0‐11.0%                                          OAMs without insulin injection for ≥3 mo                                                                                C: 144\                                                                             C: 60.0 (8.84)\    C: 82.0 (16.44)\                                         C: 8.8 (1.03)\                                          C: 11.7 (6.34)\
   NCT00548808                                                                                                                                                                                                                     EA: 103                                                                             EA: 56.2 (8.25)    EA: 66.6 (10.70)                                         EA: 8.7 (1.00)                                          EA: 9.8[a](#dmrr3062-note-0002){ref-type="fn"} (4.69)

  F3Z‐CR‐IOQI\                                          7.0‐11.0%                                          SU, BG, TZD, α‐GI, glinide, or DPP‐IV inhibitor monotherapy or combination                                              C: 29\                                                                              C: 54.0 (8.08)\    C: 79.8 (11.50)\                                         C: 9.0 (1.07)\                                          C: 10.6 (6.90)\
   NCT01773473                                                                                                                                                                                                                     EA: 374                                                                             EA: 56.7 (9.98)    EA: 68.6 (12.19)                                         EA: 8.5 (1.09)                                          EA: 9.4 (6.20)

  F3Z‐EW‐S020\                                          7.0‐11.0%                                          Met and ≥1 other OAM (SU or TZD) without insulin for ≥3 mo                                                              C: 331                                                                              C: 55.0 (8.64)     C: 84.0 (14.74)                                          C: 9.1[a](#dmrr3062-note-0002){ref-type="fn"} (1.35)    NR
   NCT00664534                                                                                                                                                                                                                                                                                                                                                                                                                                             

  F3Z‐JE‐IOPU\                                          7.5‐11.0%                                          OAMs (≥3 mo); without insulin for \<6 mo                                                                                EA: 135                                                                             EA: 60.3 (10.21)   EA: 66.6 (14.05)                                         EA: 8.3 (0.80)                                          EA: 11.4 (7.11)
   NCT00971997                                                                                                                                                                                                                                                                                                                                                                                                                                             

  F3Z‐MC‐IOHI[b](#dmrr3062-note-0003){ref-type="fn"}    HbA1c 1.2 X ULN                                    OAM (\>6 mo) and SU (max dose) and met (500‐2550 mg) for ≥1 mo                                                          C: 92                                                                               C: 56.7 (8.25)     C: 82.9 (14.90)                                          C: 9.4 (1.45)                                           C: 10.0 (7.46)

  F3Z‐MC‐IOHM[b](#dmrr3062-note-0003){ref-type="fn"}    HbA1c 1.2 X ULN                                    OAM (\>6 mo) and SU (max dose) for ≥1 mo                                                                                C: 145                                                                              C: 67.9 (4.88)     C: 78.0 (12.25)                                          C: 9.9[a](#dmrr3062-note-0002){ref-type="fn"} (1.40)    C: 11.9 (7.57)

  F3Z‐MC‐IOMY[b](#dmrr3062-note-0003){ref-type="fn"}    HbA1c \>125% X ULN within 4 weeks of study entry   Single OAM (met or second generation SU ≥3 mo) with the last ≥30 days at max dose                                       C: 531                                                                              C: 59.0 (8.83)     C: 83.6 (15.12)                                          C: 9.1[a](#dmrr3062-note-0002){ref-type="fn"} (1.44)    C: 7.6 (5.48)

  F3Z‐MC‐IOND\                                          None                                               OAMs without insulin (30 days)                                                                                          C: 78                                                                               C: 56.2 (9.73)     C: 94.6 (18.35)                                          C: 8.7[a](#dmrr3062-note-0002){ref-type="fn"} (1.19)    C: 8.8 (6.74)
   NCT00036504                                                                                                                                                                                                                                                                                                                                                                                                                                             

  F3Z‐MC‐IOOX\                                          7.5‐12.0%                                          OAM without insulin and ≥2 of: met 1500 mg/day, SU 1/2 max dose, TZD 30 mg/day pioglitazone or 4 mg/day rosiglitazone   C: 293\                                                                             C: 61.6 (9.59)\    C: 83.9 (15.45)\                                         C: 9.3 (1.17)\                                          C: 12.1 (6.89)\
   NCT00377858                                                                                                                                                                                                                     EA: 50                                                                              EA: 56.1 (9.10)    EA: 66.5 (10.42)                                         EA: 8.8 (0.87)                                          EA: 12.8 (10.05)

  F3Z‐US‐IOMN[b](#dmrr3062-note-0003){ref-type="fn"}    ≥8%                                                OAM and 1700 mg/day met for ≥3 mo                                                                                       C: 336                                                                              C: 55.2 (10.03)    C: 97.4[a](#dmrr3062-note-0002){ref-type="fn"} (19.54)   C: 9.4[a](#dmrr3062-note-0002){ref-type="fn"} (1.48)    C: 9.0[a](#dmrr3062-note-0002){ref-type="fn"} (6.06)

  F3Z‐US‐IONW[b](#dmrr3062-note-0003){ref-type="fn"}\   HbA1c 1.2‐2.0 X ULN                                ≥2 OAMs of different classes in combination for ≥2 mo                                                                   C: 45                                                                               C: 56.2 (9.59)     C: 98.4 (18.39)                                          C: 9.3[a](#dmrr3062-note-0002){ref-type="fn"} (1.28)    C: 8.9 (5.02)
   Jacober et al. Diab Metab Obes 2006;8:448‐455                                                                                                                                                                                                                                                                                                                                                                                                           

  F3Z‐US‐IOOV\                                          HbA1c 1.2‐2.0 X ULN                                ≥2 OAMs for ≥3 mo                                                                                                       C: 1319                                                                             C: 58.8 (9.45)     C: 93.5 (19.88)                                          C: 8.9[a](#dmrr3062-note-0002){ref-type="fn"} (1.17)    C: 9.8 (6.06)
   NCT00279201                                                                                                                                                                                                                                                                                                                                                                                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: α‐GI, alpha‐glucosidase inhibitor; BG, biguanide; C, Caucasian; CT.gov, ClinicalTrials.gov; DPP‐IV, dipeptidyl peptidase IV; EA, East Asian; HbA1c, glycated haemoglobin; max, maximum; met, metformin; mo, month; NR, not reported; OAM, oral antihyperglycemic medication; SD, standard deviation; SU, sulfonylurea medication; TZD, thiazolidinedione; ULN, upper limit of normal; US, United States; yr, year; wk, week.

Baseline data are not available for all patients.

Clinical trial identifier not available as the trial was conducted prior to requirements for clinical trial registration.

All patients had T2DM, were injection‐naive, and had inadequate glycemic control with OAMs at enrollment according to the study inclusion criteria. For most studies, the inclusion criteria required patients to have HbA1c \>7% at baseline (Table [1](#dmrr3062-tbl-0001){ref-type="table"}). Patients had been diagnosed with T2DM for an average of 8.9 years and had mean HbA1c levels \>7% at baseline (Table [2](#dmrr3062-tbl-0002){ref-type="table"}). However, there were significant differences between the East Asian and Caucasian groups. Compared with the Caucasian group, there was a significantly higher proportion of men in the East Asian group, and patients were significantly younger, with significantly lower body weight, body mass index, and HbA1c levels (Table [2](#dmrr3062-tbl-0002){ref-type="table"}).

###### 

Baseline characteristics of patients included in the pooled analysis

  Variable[a](#dmrr3062-note-0005){ref-type="fn"}   Caucasian Patients (*N* = 6779)   East Asian Patients (*N* = 1638)   *P* Value[b](#dmrr3062-note-0006){ref-type="fn"}
  ------------------------------------------------- --------------------------------- ---------------------------------- --------------------------------------------------
  Mean age, yr                                      57.9 (9.64)                       56.6 (10.49)                       \<0.001
  Male, n (%)                                       3687 (54.4)                       1024 (62.5)                        \<0.001
  Body weight, kg                                   91.6 (18.69)                      70.1 (12.79)                       \<0.001
  BMI, kg/m^2^                                      32.2 (5.33)                       26.0 (3.63)                        \<0.001
  Duration of T2DM, yr                              8.9 (6.05)                        8.9 (6.44)                         0.885
  HbA1c, %                                          8.6 (1.26)                        8.4 (1.04)                         \<0.001

Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; T2DM, type 2 diabetes mellitus; yr, year.

All data are mean (standard deviation) unless otherwise noted.

Fisher exact test for categorical measures, ANOVA model (response = race) for continuous measures.

### 3.1.2. Blood glucose {#dmrr3062-sec-0015}

BG excursions were highest after breakfast in both populations when adjusted for baseline body weight, baseline HbA1c, age, and duration of T2DM, and were significantly higher for East Asian patients than for Caucasian patients (Figure [1](#dmrr3062-fig-0001){ref-type="fig"}, Table [3](#dmrr3062-tbl-0003){ref-type="table"}). In addition, BG excursions were significantly higher for East Asian patients than Caucasian patients at lunch, and dinner, and for the daily average (Figure [1](#dmrr3062-fig-0001){ref-type="fig"}). Similar findings were observed for the unadjusted analyses (Table [3](#dmrr3062-tbl-0003){ref-type="table"}).

![Pooled analysis of blood glucose excursion for East Asian and Caucasian injection‐naive patients with inadequate glycemic control after oral antihyperglycemic medication. Data are reported as the adjusted least‐squares mean difference between postprandial and preprandial blood glucose at each time point. Error bars denote standard error of the mean. \* Blood glucose excursions between East Asians and Caucasians were significantly different at each time point (*P* \< 0.001, adjusted ANCOVA)](DMRR-34-na-g001){#dmrr3062-fig-0001}

###### 

Pooled analysis of blood glucose profiles and excursion for East Asian and Caucasian injection‐naive patients with inadequate glycemic control after oral antihyperglycemic medication

  Time Point                                                Unadjusted Preprandial BG[a](#dmrr3062-note-0008){ref-type="fn"}, mmol/L   Adjusted Preprandial BG[b](#dmrr3062-note-0009){ref-type="fn"}, mmol/L          Unadjusted Postprandial BG[a](#dmrr3062-note-0008){ref-type="fn"}, mmol/L   Adjusted Postprandial BG[b](#dmrr3062-note-0009){ref-type="fn"}, mmol/L          Unadjusted BG Excursion[a](#dmrr3062-note-0008){ref-type="fn"}, mmol/L   Adjusted BG Excursion[b](#dmrr3062-note-0009){ref-type="fn"}, mmol/L
  -------------------------------------------------- ------ -------------------------------------------------------------------------- ------------------------------------------------------------------------ ------ --------------------------------------------------------------------------- ------------------------------------------------------------------------- ------ ------------------------------------------------------------------------ ----------------------------------------------------------------------
  Morning                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Caucasian                                          3791   9.92 (2.806)                                                               9.76 (0.035)                                                             3733   12.49 (3.689)                                                               12.32 (0.051)                                                             3728   2.60 (2.495)                                                             2.59 (0.045)
  East Asian                                         1430   9.20 (2.228)                                                               9.61 (0.060)                                                             1432   13.22 (3.390)                                                               13.63 (0.085)                                                             1430   4.02 (2.757)                                                             4.03 (0.075)
  *P* value[c](#dmrr3062-note-0010){ref-type="fn"}          \<0.001                                                                    0.048                                                                           \<0.001                                                                     \<0.001                                                                          \<0.001                                                                  \<0.001
  Midday                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Caucasian                                          3524   9.95 (3.435)                                                               9.82 (0.047)                                                             3490   11.36 (3.480)                                                               11.23 (0.051)                                                             3473   1.44 (2.449)                                                             1.43 (0.049)
  East Asian                                         1426   9.48 (3.059)                                                               9.82 (0.078)                                                             1425   12.97 (3.392)                                                               13.19 (0.082)                                                             1425   3.48 (3.006)                                                             3.37 (0.080)
  *P* value[c](#dmrr3062-note-0010){ref-type="fn"}          \<0.001                                                                    0.960                                                                           \<0.001                                                                     \<0.001                                                                          \<0.001                                                                  \<0.001
  Evening                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Caucasian                                          3766   10.02 (3.345)                                                              9.88 (0.046)                                                             3742   11.77 (3.501)                                                               11.60 (0.049)                                                             3729   1.78 (2.408)                                                             1.74 (0.047)
  East Asian                                         1426   9.53 (3.150)                                                               9.85 (0.078)                                                             1419   12.65 (3.493)                                                               12.97 (0.083)                                                             1417   3.14 (3.112)                                                             3.16 (0.080)
  *P* value[c](#dmrr3062-note-0010){ref-type="fn"}          \<0.001                                                                    0.767                                                                           \<0.001                                                                     \<0.001                                                                          \<0.001                                                                  \<0.001
  Daily                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Caucasian                                          3747   9.98 (2.877)                                                               9.82 (0.034)                                                             3699   11.90 (3.220)                                                               11.74 (0.040)                                                             3684   1.96 (1.524)                                                             1.95 (0.028)
  East Asian                                         1427   9.41 (2.431)                                                               9.80 (0.058)                                                             1425   12.95 (2.923)                                                               13.28 (0.068)                                                             1424   3.55 (1.791)                                                             3.51 (0.048)
  *P* value[c](#dmrr3062-note-0010){ref-type="fn"}          \<0.001                                                                    0.727                                                                           \<0.001                                                                     \<0.001                                                                          \<0.001                                                                  \<0.001

Abbreviations: BG, blood glucose; HbA1c, glycated haemoglobin; LS least‐squares; SD, standard deviation; SE, standard error of the mean.

ANCOVA with race as a fixed effect.

Adjusted for baseline body weight, age, duration of type 2 diabetes mellitus, and baseline HbA1c.

Differences between East Asian and Caucasian groups.

BG profiles were significantly different between East Asian and Caucasian patients (Figure [2](#dmrr3062-fig-0002){ref-type="fig"}, Table [3](#dmrr3062-tbl-0003){ref-type="table"}). In the unadjusted analysis, preprandial BG was significantly lower and postprandial BG was significantly higher for East Asian patients than for Caucasian patients at all time points (Figure [2](#dmrr3062-fig-0002){ref-type="fig"}A). The differences in preprandial BG at lunch, dinner, and for the daily preprandial average between East Asian and Caucasian patients were not significant when the analyses were adjusted for baseline body weight, baseline HbA1c, age, and duration of T2DM. However, differences between East Asian and Caucasian patients in all postprandial BG levels remained significant after adjustment for these factors (Figure [2](#dmrr3062-fig-0002){ref-type="fig"}B, Table [3](#dmrr3062-tbl-0003){ref-type="table"}).

![Pooled analysis of blood glucose profiles for East Asian and Caucasian injection‐naive patients with inadequate glycemic control after oral antihyperglycemic medication. A, Unadjusted mean preprandial and postprandial blood glucose at each time point. B, Adjusted least‐squares mean preprandial and postprandial blood glucose at each time point. Error bars are not visible as they are within the symbols for each data point. Unadjusted preprandial and postprandial blood glucose and adjusted postprandial blood glucose were significantly different between Caucasians and East Asians at all time points (\**P* \< 0.001, ANCOVA); adjusted prebreakfast blood glucose was significantly higher in Caucasians than in East Asians (*P* = 0.048)](DMRR-34-na-g002){#dmrr3062-fig-0002}

3.2. Systematic review of the literature {#dmrr3062-sec-0016}
----------------------------------------

Five publications met the eligibility criteria for the systematic review; four studies reported findings in Caucasian populations[14](#dmrr3062-bib-0014){ref-type="ref"}, [15](#dmrr3062-bib-0015){ref-type="ref"}, [16](#dmrr3062-bib-0016){ref-type="ref"}, [17](#dmrr3062-bib-0017){ref-type="ref"} and one study[12](#dmrr3062-bib-0012){ref-type="ref"} reported findings separately for Caucasian and/or East Asian populations. There was a tendency for higher BG excursions at breakfast, lunch, and dinner in East Asian patients than in Caucasian patients (Supplementary Table [S1](#dmrr3062-supitem-0001){ref-type="supplementary-material"}). However, there was a high level of variability in BG excursions within each study and between each of the study populations. Meta analyses were not conducted because there were insufficient data to compare East Asian with Caucasian populations. Details of the search results are reported in the Supplementary Appendix.

4. DISCUSSION {#dmrr3062-sec-0017}
=============

This study is the first to compare BG profiles of injection‐naive East Asian patients and Caucasian patients with T2DM and an inadequate glycemic response to OAMs using a pooled analysis of patient‐level data. Overall, this large, retrospective pooled analysis of 8417 injection‐naive patients with T2DM demonstrated higher postprandial BG levels and greater BG excursions in East Asian patients compared with Caucasian patients following breakfast, lunch, and dinner. These findings were evident even after adjusting for patient body weight, baseline HbA1c, age, and duration of T2DM. Evidence from the peer‐reviewed literature was limited and, of the five studies retrieved, only one study reported BG profiles of East Asian patients.[12](#dmrr3062-bib-0012){ref-type="ref"} However, findings from the literature were generally supportive of the pooled analysis. Overall, this study supports evidence from studies conducted in Taiwan and Japan[10](#dmrr3062-bib-0010){ref-type="ref"}, [11](#dmrr3062-bib-0011){ref-type="ref"} and a post hoc subgroup analysis of patients from China and the Republic of Korea[12](#dmrr3062-bib-0012){ref-type="ref"} that postprandial BG is an important treatment target among East Asian patients with T2DM.

Given the complex pathophysiology of T2DM, the reasons for the difference in BG profiles between East Asian and Caucasian populations are likely to be multifactorial and related to both lifestyle and diet, and to ethnic differences in insulin resistance and the capacity to secrete insulin.[7](#dmrr3062-bib-0007){ref-type="ref"} Asian populations have higher glycemia in response to the same carbohydrate load[4](#dmrr3062-bib-0004){ref-type="ref"} and higher daily intake of carbohydrate compared with Caucasian populations.[9](#dmrr3062-bib-0009){ref-type="ref"}, [10](#dmrr3062-bib-0010){ref-type="ref"} Greater insulin resistance is observed in Asian populations, possibly because of higher levels of visceral fat per body weight or waist circumference compared with Caucasian populations.[5](#dmrr3062-bib-0005){ref-type="ref"}, [18](#dmrr3062-bib-0018){ref-type="ref"} Also the capacity to secrete insulin appears to have a more predominant role in T2DM among Asian populations compared with Caucasians, particularly in those who are of lean body weight.[7](#dmrr3062-bib-0007){ref-type="ref"}, [19](#dmrr3062-bib-0019){ref-type="ref"}, [20](#dmrr3062-bib-0020){ref-type="ref"}, [21](#dmrr3062-bib-0021){ref-type="ref"} In this study, East Asian patients were of lower body weight than their Caucasian counterparts. However, the differences in BG profiles remained statistically significant after adjustment for body weight (as well as baseline HbA1c, age, and duration of T2DM) in the analyses.

Differences in BG profiles among patients with T2DM of different races and ethnicities may have implications for how T2DM is managed and for treatment outcomes. Patients in Asia have earlier onset and longer duration of T2DM and are at a higher risk of microvascular complications, particularly renal disease, compared with Caucasians.[5](#dmrr3062-bib-0005){ref-type="ref"}, [22](#dmrr3062-bib-0022){ref-type="ref"}, [23](#dmrr3062-bib-0023){ref-type="ref"} Analysis of BG profiles among Caucasian patients with T2DM who were insulin‐naive has shown that the contribution of postprandial BG to excess hyperglycemia decreases relative to fasting BG in poorly controlled patients.[24](#dmrr3062-bib-0024){ref-type="ref"} In contrast, several studies have shown that targeting postprandial BG is as important as targeting preprandial BG for management of hyperglycemia among East Asian patients who are poorly controlled on OAMs, before receiving injectable treatment[10](#dmrr3062-bib-0010){ref-type="ref"} and among those on insulin.[10](#dmrr3062-bib-0010){ref-type="ref"}, [11](#dmrr3062-bib-0011){ref-type="ref"} Analysis of Asian patients with T2DM who were insulin‐naive has shown that the contribution of postprandial BG to 4‐hour excess hyperglycemia after meals and 24‐hour excess hyperglycemia is similar to the contribution of preprandial BG/fasting BG, respectively, in poorly controlled patients (HbA1c \>7%).[10](#dmrr3062-bib-0010){ref-type="ref"} In addition, findings from a retrospective post hoc analysis of patients with T2DM of different ethnicities showed that Asian patients had a greater need for, and higher doses of, mealtime insulin than non‐Asian patients on basal insulin glargine plus prandial insulin lispro.[12](#dmrr3062-bib-0012){ref-type="ref"} Together with the current study, these findings suggest that postprandial BG is an important treatment target in East Asian populations and suggests that East Asian patients may have a greater and earlier need of therapies. Indeed, assessment of treatment patterns from noninterventional studies has shown that use of premixed insulins in Asian populations is widespread, with approximately one‐third of Japanese patients commencing insulin with a premixed insulin[25](#dmrr3062-bib-0025){ref-type="ref"} and approximately two‐thirds of Chinese patients on OAMs using a premixed insulin.[26](#dmrr3062-bib-0026){ref-type="ref"}

The main strength of this study was the large number of patients available for analysis from multiple clinical studies with similar eligibility criteria and procedures. Significant differences in BG profiles and excursions between the East Asian and Caucasian groups were observed in the unadjusted analyses and after analyses were adjusted to take into account differences in baseline characteristics between the groups. However, interpretation of the findings should take into account the retrospective nature of the analyses and that the included studies were not designed to compare BG profiles of patients from different ethnicities. As this was a post‐hoc pooled analysis, our intention was to show whether there were differences in BG profiles between the two ethnic groups. We did not match the baseline characteristics and demographics between East Asian and Caucasian patients. Therefore, it was impossible to explore the reasons for the differences observed in this study. Although the included clinical studies were very similar in design, the interpretation of the findings should take into account that data were pooled data from two clinical trial programs that were conducted at different times, and that included patients with various OAM treatment regimens, and patients from different Caucasian populations. The systematic review of the literature confirmed the rationale for conducting a pooled analysis and showed that there is limited information in the peer‐reviewed literature on postprandial BG before commencing injectable treatment. Moreover, there was a high degree of variability in the data available from the peer‐reviewed literature; only one study included data on BG excursion at baseline and only one study reported on BG excursions in East Asian patients.

In conclusion, findings from this retrospective pooled analysis of individual patient data showed significantly higher postprandial BG excursions in East Asian patients with T2DM who were injection‐naive and had inadequate glycemic control with OAMs compared with Caucasian patients. These findings have clinical implications for the effect of ethnicity on the BG profiles in patients with T2DM and suggest that there should be greater emphasis on the control of BG excursions in East Asian patients. In addition, these findings may help clinicians select appropriate treatments for East Asian patients with T2DM who require injection therapy.
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